TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15390323

Group type: EXPERIMENTAL
Intervention: fenoldopam 0.1 microg/kg/minute
Number of subjects: 140

Group type: COMPARATOR
Intervention: dopamine 3 microg/kg/minute
Number of subjects: 140

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 140
Study: 11606878

Group type: EXPERIMENTAL
Intervention: One of the QI interventions
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1136
Study: 9672274

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg per day orally
Number of subjects: 2494

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2494
Study: 8065798

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 16
Study: 3338232

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.15 mg/kg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.30 mg/kg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.50 mg/kg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29637529

Group type: EXPERIMENTAL
Intervention: ND0701
Number of subjects: 34

Group type: COMPARATOR
Intervention: APO-go®
Number of subjects: 34
Study: 27701366

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 116

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 116
Study: 23514730

Group type: EXPERIMENTAL
Intervention: sE-selectin
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: PAI-1 (total and active)
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: TNFR-1 and TNFR-2
Number of subjects: 1237
Study: 20094015

Group type: EXPERIMENTAL
Intervention: 1-mg estradiol and 0.5-mg norethisterone (hormone therapy)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 19035712

Group type: EXPERIMENTAL
Intervention: Elective surgical exploration
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Urgent decompression of the clot
Number of subjects: 9
Study: 15974555

Group type: EXPERIMENTAL
Intervention: Nurse-administered 6-month telephonic case management intervention (Asthma Treatment Awareness Project)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 0
Study: 11890972

Group type: COMPARATOR
Intervention: 27 degrees C (thermoneutral zone)
Number of subjects: 3
Study: 10503585

Group type: EXPERIMENTAL
Intervention: Lamotrigine (25 mg for 2 weeks, 50 mg for 2 weeks, and 100 mg for 4 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo tablets (taken once daily)
Number of subjects: 31
Study: 8941876

Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 (1.2 x 10(6) IU/m2)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High-dose IL-2 (1.2 x 10(7) IU/m2)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No adjuvant IL-2
Number of subjects: 17
Study: 2010875

Group type: EXPERIMENTAL
Intervention: CNS prophylaxis treatment including cranial irradiation and intrathecal methotrexate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CNS prophylaxis treatment including only intrathecal methotrexate and intermediate dose infusions of methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Learning disabled (LD) children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leukemic children
Number of subjects: 0
Study: 7023527

Group type: EXPERIMENTAL
Intervention: Sustained-release aminophylline
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31009405

Group type: EXPERIMENTAL
Intervention: Allogenic Fecal Microbiota Transfer (FMT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Autologous Fecal Microbiota Transfer (FMT)
Number of subjects: 17
Study: 29177031

Group type: EXPERIMENTAL
Intervention: Core Stabilization Training Program (CSTP), 16 sessions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Core Stabilization Training Program (CSTP)
Number of subjects: 0
Study: 26391365

Group type: EXPERIMENTAL
Intervention: High pump speed setting
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low pump speed setting
Number of subjects: 10
Study: 24042304

Group type: EXPERIMENTAL
Intervention: Hyperoxic recovery (FiO2 = 1.00)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hypoxic recovery (FiO2 ∼ 0.165)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hyperoxic recovery
Number of subjects: 8
Study: 22734028

Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemotherapy
Number of subjects: 1378

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1378
Study: 19957798

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose Methotrexate + Leflunomide (MTX + LEF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MTX + LEF
Number of subjects: 0

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (MTX, LEF, MTX + LEF)
Number of subjects: 0
Study: 17922442

Group type: EXPERIMENTAL
Intervention: Optimal glycemic control (HbA1c below 7.0%) in normoalbuminuric patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood pressure control below 130/80 mmHg in normoalbuminuric patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strict glycemic control (HbA1c below 7.0%) in microalbuminuric patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood pressure control below 130/80 mmHg in microalbuminuric patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhibition of RAAS (ACE-I or ARB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE-I in type 1 diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ARB in type 2 diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multifactorial therapeutic approach (glycemic control, antihypertensive therapy, RAAS inhibition, statins, aspirin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal blood pressure levels < 130/80 mmHg for proteinuria < 1 g/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal blood pressure levels < 120/75 mmHg for proteinuria ≥ 1 g/day
Number of subjects: 0
Study: 15781600

Group type: EXPERIMENTAL
Intervention: Psycho-educational program (10 weekly sessions)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 82
Study: 11981724

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (90 mg/kg per day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated, healthy subjects)
Number of subjects: 0
Study: 9609359

Group type: EXPERIMENTAL
Intervention: alpha‐tocopherol nicotinate 300 mg tds after meals for 3 months
Number of subjects: 13
Study: 8553592

Group type: EXPERIMENTAL
Intervention: Spirapril monotherapy
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Spirapril + Bopindolol
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Spirapril + Hydrochlorothiazide
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Overall treatment (all groups)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Spirapril
Number of subjects: 171
Study: 2797894

Group type: EXPERIMENTAL
Intervention: 1.5 g of cefamandole at induction of anaesthesia and 750 mg every six hours during 24 hours after surgery
Number of subjects: 122

Group type: COMPARATOR
Intervention: Single injection of 1.5 g of cefamandole at induction of anaesthesia
Number of subjects: 122
Study: 381229

Group type: EXPERIMENTAL
Intervention: 1000 mg ascorbic acid daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4000 mg ascorbic acid daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30709437

Group type: EXPERIMENTAL
Intervention: ATLG plus standard GVHD prophylaxis (ciclosporin and short-term methotrexate)
Number of subjects: 155
Study: 30069600

Group type: EXPERIMENTAL
Intervention: Dydrogesterone (20 mg/day) plus HMG (150 or 225 IU)
Number of subjects: 251

Group type: COMPARATOR
Intervention: GnRH antagonist protocol
Number of subjects: 251
Study: 27300114

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen
Number of subjects: 102

Group type: COMPARATOR
Intervention: Not applicable (before HT)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Not applicable (after 48 months of treatment)
Number of subjects: 102
Study: 25112084

Group type: EXPERIMENTAL
Intervention: Acupuncture at Baihui (GV 20), Sishencong (EX‐HN 1), Neiguan (PC 6), Zusanli (ST 36), and Hegu (LI 4) for 20 minutes, twice a week for 10 treatments.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delayed acupuncture (no treatment during observation stage).
Number of subjects: 60
Study: 22192643

Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine 80/5 mg (single dose)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine 80/5 mg (multiple dose, once-daily for 9 days)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Valsartan/Amlodipine 80/5 mg (single and multiple doses)
Number of subjects: 18
Study: 19154523

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids, vitamin C and Zn supplementation
Number of subjects: 60
Study: 17614302

Group type: EXPERIMENTAL
Intervention: Vinorelbine plus trastuzumab
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Taxane plus trastuzumab
Number of subjects: 81
Study: 15474698

Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 450

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 450
Study: 11793614

Group type: EXPERIMENTAL
Intervention: cilomilast 15 mg twice daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 9745987

Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg), administered 2 hr before habitual bedtime
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study: 7973770

Group type: EXPERIMENTAL
Intervention: Vinorelbine (Navelbine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil/leucovorin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine
Number of subjects: 0
Study: 2467328

Group type: EXPERIMENTAL
Intervention: Low-fibre diet during and after first cycle of cisplatin and vinblastine chemotherapy (Group 1)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Vinblastine (Group 2)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16) instead of vinblastine (Group 3)
Number of subjects: 55
Study: 31027081

Group type: EXPERIMENTAL
Intervention: PHILOS plate with custom neutral-position shoulder and elbow sling for 30 days after surgery
Number of subjects: 112

Group type: COMPARATOR
Intervention: PHILOS plate alone
Number of subjects: 112
Study: 29722943

Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate Pills (TUP)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (maintaining glucose- and lipid-reducing therapies)
Number of subjects: 82
Study: 26226091

Group type: EXPERIMENTAL
Intervention: self-help CBT-I with telephone support
Number of subjects: 207

Group type: COMPARATOR
Intervention: self-help CBT-I
Number of subjects: 207
Study: 24141628

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg orally once daily
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1199
Study: 21358317

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline, 0.9%)
Number of subjects: 40
Study: 18285378

Group type: EXPERIMENTAL
Intervention: Hyperalimented feeding regimen from birth to 34 weeks' postmenstrual age (PMA)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard feeding regimen from birth to 34 weeks' postmenstrual age (PMA)
Number of subjects: 109
Study: 16957145

Group type: EXPERIMENTAL
Intervention: Adjuvant cisplatin-based chemotherapy
Number of subjects: 761

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 761

Group type: COMPARATOR
Intervention: No adjuvant chemotherapy (Control)
Number of subjects: 761
Study: 12859309

Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lidocaine 2.5 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (Saline)
Number of subjects: 12
Study: 16159930

Group type: EXPERIMENTAL
Intervention: Depot GH (n = 51)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Daily GH (n = 53)
Number of subjects: 135

Group type: COMPARATOR
Intervention: No treatment (n = 31)
Number of subjects: 135
Study: 10344296

Group type: COMPARATOR
Intervention: CHX (0.00025% chlorhexidine acetate)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CHX+EDG (0.00025% chlorhexidine acetate with 0.005% ethyl‐6‐O‐decanoyl‐glucoside)
Number of subjects: 19
Study: 8568292

Group type: EXPERIMENTAL
Intervention: Ritonavir
Number of subjects: 21
Study: 1779084

Group type: EXPERIMENTAL
Intervention: Active based cream F14001
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo non-active based cream
Number of subjects: 0
Study: 6111331

Group type: EXPERIMENTAL
Intervention: 40 mg betaxolol
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 200 mg atenolol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 160 mg propranolol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 160 mg oxprenolol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 400 mg sotalol
Number of subjects: 5
Study: 31122797

Group type: EXPERIMENTAL
Intervention: Maternal triple antiretroviral treatment throughout both ante‐partum and post‐partum phases
Number of subjects: 861

Group type: COMPARATOR
Intervention: Maternal non-adherence to triple antiretroviral treatment
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: Maternal triple antiretroviral treatment
Number of subjects: 861

Group type: COMPARATOR
Intervention: HIV-unexposed and uninfected children
Number of subjects: 861
Study: 26024922

Group type: EXPERIMENTAL
Intervention: Limiting bonuses
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Self-exclusion
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Self-limitation
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Information
Number of subjects: 485

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 485
Study: 24267180

Group type: EXPERIMENTAL
Intervention: High-fat diet enriched with milk minerals (MM group)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: High-fat diet enriched with milk minerals (MM period)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control period (regular diet)
Number of subjects: 33
Study: 21937519

Group type: EXPERIMENTAL
Intervention: Aerobic training (Group 1, n = 18)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Aerobic with strength training (Group 2, n = 18)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Untrained (Group 3, n = 14)
Number of subjects: 50
Study: 19116943

Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17170562

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 414
Study: 15147224

Group type: EXPERIMENTAL
Intervention: Full-time school nurses (5 days/week)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Part-time school nurses (2 days/week)
Number of subjects: 14
Study: 11824107

Group type: EXPERIMENTAL
Intervention: Prophylactic appendectomy with invaginant technic during cesarean section
Number of subjects: 59

Group type: COMPARATOR
Intervention: Cesarean section only
Number of subjects: 59
Study: 10193231

Group type: EXPERIMENTAL
Intervention: remifentanil 1.0 microgram.kg‐1
Number of subjects: 80

Group type: COMPARATOR
Intervention: saline placebo (control)
Number of subjects: 80
Study: 8070935

Group type: EXPERIMENTAL
Intervention: Amphotericin B alone (0.5 mg/kg/day; n = 14)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Amphotericin B (0.5 mg/kg/day) plus 5-flucytosine (150 mg/kg/day; n = 14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Amphotericin B alone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Amphotericin B plus 5-flucytosine
Number of subjects: 28
Study: 31469593

Group type: COMPARATOR
Intervention: Hyrax (H)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Quad-helix (QH)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Expander with differential opening (EDO)
Number of subjects: 75
Study: 31561960

Group type: EXPERIMENTAL
Intervention: Atorvastatin (0.125-0.75 mg/kg/day)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Atorvastatin (0.75 mg/kg/day)
Number of subjects: 34
Study: 28006725

Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26619915

Group type: EXPERIMENTAL
Intervention: Training using expression morph sequences for happy expressions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training using expression morph sequences for fearful expressions
Number of subjects: 0
Study: 23853246

Group type: EXPERIMENTAL
Intervention: Ixabepilone 40 mg/m2 (3‐hour infusion) every 3 weeks for four cycles
Number of subjects: 295

Group type: COMPARATOR
Intervention: Weekly paclitaxel 80 mg/m2 (1‐hour infusion) for 12 weeks
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Ixabepilone
Number of subjects: 295

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Both ixabepilone and paclitaxel
Number of subjects: 295
Study: 21214498

Group type: EXPERIMENTAL
Intervention: Internet-based self-management system utilizing e-PHR, including secure messaging, self-monitoring, self-management of MS symptoms, and communication about upcoming clinic visits.
Number of subjects: 206

Group type: COMPARATOR
Intervention: Usual care (secure Web-based messaging system)
Number of subjects: 206
Study: 18290863

Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard medical treatment (Control)
Number of subjects: 30
Study: 16817265

Group type: EXPERIMENTAL
Intervention: Phased whole acupuncture therapy
Number of subjects: 113

Group type: COMPARATOR
Intervention: Traditional acupuncture
Number of subjects: 113
Study: 12923621

Group type: EXPERIMENTAL
Intervention: Enteral glutamine (20 g/l)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Control (isonitrogenous and isojoulic solution)
Number of subjects: 363
Study: 11203620

Group type: EXPERIMENTAL
Intervention: Bar attachment system
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ball attachment system
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both bar and ball attachment systems
Number of subjects: 26
Study: 8959854

Group type: EXPERIMENTAL
Intervention: IMM 125
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sandimmun
Number of subjects: 70
Study: 8237969

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (3 g of calcium carbonate daily)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sucrose placebo
Number of subjects: 68
Study: 3815460

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (100 micrograms daily for nine weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (after switching from placebo)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline placebo (after switching from interferon)
Number of subjects: 40
Study: 29555213

Group type: EXPERIMENTAL
Intervention: Dietary habits and physical activity assessment using Food Frequency Questionnaire (FFQ) and Physical Activity Scale (PAS)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Physical activity assessment
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Association of negative symptoms with dietary quality and physical activity
Number of subjects: 428
Study: 26385817

Group type: EXPERIMENTAL
Intervention: No formal education
Number of subjects: 9270

Group type: COMPARATOR
Intervention: Education level
Number of subjects: 9270
Study: 24512975

Group type: EXPERIMENTAL
Intervention: Attention Modification Program (AMP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Attentional Control Program (ACC)
Number of subjects: 24
Study: 21083771

Group type: EXPERIMENTAL
Intervention: Inhalation of 40 puffs of 0.2 mg salbutamol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (two placebo tablets)
Number of subjects: 9
Study: 20532528

Group type: EXPERIMENTAL
Intervention: Modified transanal endorectal pull-through (TEPT) procedure (Group B)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional TEPT procedure (Group A)
Number of subjects: 45
Study: 18797274

Group type: EXPERIMENTAL
Intervention: Fluid restriction and bladder retraining
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New anticholinergic medications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravesical botulinum toxin
Number of subjects: 0
Study: 15983464

Group type: EXPERIMENTAL
Intervention: Sequential Epidural Bolus (SEB) technique
Number of subjects: 16

Group type: COMPARATOR
Intervention: Continuous Epidural Infusion (CEI) technique
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Difference in blocked segments between sides in SEB group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Difference in blocked segments between sides in CEI group
Number of subjects: 16
Study: 12209503

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: 1 mg tacrolimus
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: 3 mg tacrolimus
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: 5 mg tacrolimus
Number of subjects: 268
Study: 10494483

Group type: EXPERIMENTAL
Intervention: DMPA
Number of subjects: 100

Group type: COMPARATOR
Intervention: IUD
Number of subjects: 100
Study: 7476742

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg oral tablet on admission, followed by 50 mg infusion in 250 ml dextrose 5% over 30 minutes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cimetidine (400 mg oral tablet and 100 mg infusion in 250 ml dextrose 5% over 30 minutes)
Number of subjects: 20